Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pfizer Obtains Approval for Generics of 14 APIs
August 1, 2011
- US FDA Announces Draft Guidance for Simultaneous Development of Therapeutics and Companion Diagnostic Devices
August 1, 2011
- Daiichi Sankyo Espha to Deal with Both Long-listed Products, Generics
August 1, 2011
- Biosimilars Optimize Healthcare Costs: JSGM Seminar
August 1, 2011
- AZ, NCC Announce Comprehensive Agreement for Development of Anticancer Drugs
August 1, 2011
- Eisai Launches Halaven in Japan; Product to Be Detailed by All 1,400 MRs
August 1, 2011
- Volume-based Generics Market Share Up to 23.0% in FY 2010: JGA
August 1, 2011
- Shionogi Starts 4th PIII Study of the HIV Treatment S-349572
August 1, 2011
- Daiichi Sankyo Launches Lixiana for Prevention of VTE
August 1, 2011
- JGA Compiles Model Corporate Ethics Standards
August 1, 2011
- Takeda to Beef Up Its OTC Drugs Business in Asia
August 1, 2011
- RaQualia Listed on JASDAQ; Aims to Raise ¥6.3 Bil.
August 1, 2011
- MTPC Ordered to Stop Operations for 10 Days at Subsidiary Plant
August 1, 2011
- Japan Federation of Non-prescription Medicines Industry Set Up by 5 Organizations
August 1, 2011
- Astellas to Drive Business in Emerging Markets Based on GCL Strategy: Vice Deputy Chairman Ishii
August 1, 2011
- Council Starts Discussing How to Realize Proposed Social Security/Tax Reform Plan
August 1, 2011
- 3 Vaccines Judged to Be Safe “at Present Time”: PAFSC Study Groups
August 1, 2011
- Chugai: Operating Profits Up 27% in 1st Half
August 1, 2011
- EMA Asks Takeda to Revise Package Inserts for Pioglitazone Medicines Due to Risk of Bladder Cancer
August 1, 2011
- PAFSC Subcommittee Recommends Classification of 4 Crude Drugs as Class 2 OTC Drugs
August 1, 2011
ページ
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…